<div class="p4l_caption"><div class="p4l_captionTitle"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4322980/" ref="ordinalpos=4602&amp;ncbi_uid=7163122&amp;link_uid=PMC4322980" image-link="/pmc/articles/PMC4322980/figure/F4/" class="imagepopup">Figure 4. GANT-61 treatment dampens Shh and m-TOR <span class="highlight" style="background-color:">signaling</span> pathways.  From: GLI inhibitor GANT-61 diminishes embryonal and alveolar rhabdomyosarcoma growth by inhibiting Shh/AKT-mTOR axis. </a></div><br /><div class="p4l_captionBody"><b>(A)</b> Semi-quantitative RT-PCR analysis of Gli1/2 in RD and RH30 cells at various concentrations of GANT-61. <b>(B)</b> Immunofluorescence staining of GLI1 in vehicle-and GANT-61-treated RH30 cells-derived xenograft tumors. <b>(C)</b> Real time PCR analysis of Gli1 mRNA expression relative to GAPDH as an internal control in GANT-61-treated xenograft tumors as compared to vehicle-treated control tumors. AKT/mTOR signaling pathway proteins in GANT-61-treated RD and RH30 cells-derived tumors vs. vehicle-treated control tumors: <b>(D)</b> Real time PCR analysis and <b>(E-I &amp; EII)</b> western blot analysis. <b>(F)</b> Western blot analysis of GANT-61 on the phosphorylation of AKT/mTOR signaling pathway proteins (p-AKT, p-mTOR, p-P70S6K) in RD and RH30 RMS cells. T1 to T4 represents tumors excised from four different mice. P value represents level of significant difference in GANT-61-treated and vehicle-treated controls.</div></div>